PharmaBoardroom

The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his…

Bene Farmacêutica was established in 2009 to expand the supply and presence of Bene-Arzneimittel in Portugal, having already sold products in the…

In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on Taiwan‰Ûªs stock exchange, the…

Karim El-Alaoui Mustapha, Managing Diretor of Boehringer Ingelheim, MENA, talks about the company’s two-fold strategy in attracting, and…

A round-table discussion with leading figures from Taiwan's NHRI, covering perspectives on the current state of the Taiwanese healthcare and…

Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are…

What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit…

Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the…

Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we…

Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company…

You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this…

While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general…